EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

Agnieszka Jakubowska, Carel W le Roux, Adie Viljoen

Endocrinology and Metabolism · 29.02.2024 · 39 (1) · 12-22

DOI: 10.3803/enm.2024.1942 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 29.02.2024. Verfasst von Agnieszka Jakubowska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2, Receptors, Gastrointestinal Hormone. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science Foundation Ireland, Health Research Board, Amarin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood pressure, inflammation, and hepatic steatosis. The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Diabetes Mellitus, Type 2Receptors, Gastrointestinal HormoneHumansReceptors, GlucagonGastric Inhibitory PolypeptideObesityWeight LossReceptors, G-Protein-CoupledGlucoseRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Gastric inhibitory polypeptideGlucagonGlucagon-like peptide 1ObesityTriagonistsTriple agonistsWeight loss

Substanzen

Glucagon-Like Peptide 1Receptors, Glucagongastric inhibitory polypeptide receptorGastric Inhibitory PolypeptideReceptors, G-Protein-CoupledGlucoseReceptors, Gastrointestinal Hormone

Autor:innen und Institutionen

  • Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK.
  • Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.

Förderung

  • Science Foundation Ireland
  • Health Research Board
  • Amarin
  • Amgen
  • Astra Zeneca
  • Boehringer Ingleheim
  • Daiichi-Sankyo
  • Eli Lilly Japan

Zitieren

APA

Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinology and Metabolism, 39(1), 12-22. https://doi.org/10.3803/enm.2024.1942

Vancouver

Jakubowska A, Roux CWL, Viljoen A. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinology and Metabolism. 2024;39(1):12-22. doi:10.3803/enm.2024.1942

BibTeX
@article{Jakubowska2024,
  author = {Jakubowska, Agnieszka and Roux, Carel W le and Viljoen, Adie},
  title = {The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  volume = {39},
  number = {1},
  pages = {12--22},
  doi = {10.3803/enm.2024.1942}
}
Kostenlos starten →